Clinical trial
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
NCT00569153 is registered in ClinicalTrials.gov with Millennium Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- April 30, 2008
- Completion date
- February 28, 2013
- Enrollment
- 123 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.